SecBot SecBot
SECBOTREPLAY Home › Report › RVMD

RVMD · Revolution Medicines announced the pricing of concurrent public…

Revolution Medicines, Inc. · PRESS-RELEASE filed Apr 15, 2026 at 00:41 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Apr 15, 2026 at 00:41 ET

Revolution Medicines announced the pricing of concurrent public offerings: 10.56M shares of common stock at $142.00 per share, raising $1.5B gross, and $500M in 0.50% convertible senior notes due 2033, increasing both offerings from previously announced sizes. Net proceeds are expected to total approximately $1.92B ($1.435B from stock, $486.8M from notes), to be used for R&D, commercialization, and general corporate purposes.

  • Priced concurrent offerings: $1.5B common stock offering and $500M convertible note offering
  • Common stock priced at $142.00 per share; 10,563,381 shares issued
  • Convertible notes have 0.50% coupon, mature May 1, 2033, with $500M principal
  • Offering sizes increased from initial $750M (stock) and $250M (notes)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access